Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Cancer Lett. 2019 Jul 6;461:1–9. doi: 10.1016/j.canlet.2019.07.002

Figure 6. Analysis of immune cells from the peritoneal lavage fluid upon treatment with combination miR-125b transfection and paclitaxel chemotherapy.

Figure 6.

Female C57BL/6 mice were injected with ID8 cells on day 1. On day 8th mice were injected intraperitoneally with PTX (2 mg/kg) and on day 10th mice were injected intraperitoneally with either HA-PEI-scrambled miR or HA-PEI-miR-125b at 1 mg/kg dose every alternate day for 3 days and peritoneal cavity was lavaged with 1X PBS. Peritoneal cells were collected and analysed by FACS for (A) CD11b+, F4/80+ macrophages, (B) CD206+ M2 macrophages and (C) CD80+ M1 macrophages (D) Ratio of CD206+/CD80+ cells. N=4, Data is analyzed by One-way ANOVA. (F) Schematic representation of combination therapy with intraperitoneal administration of HA-PEI-miR-125b nanoparticles and paclitaxel as anticancer therapy for epithelial ovarian cancer.